Authors:
Rudin, CM
Holmlund, J
Fleming, GF
Mani, S
Stadler, WM
Schumm, P
Monia, BP
Johnston, JF
Geary, R
Yu, RZ
Kwoh, TJ
Dorr, FA
Ratain, MJ
Citation: Cm. Rudin et al., Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer, CLIN CANC R, 7(5), 2001, pp. 1214-1220
Authors:
Gao, Q
Tomlinson, G
Das, S
Cummings, S
Sveen, L
Fackenthal, J
Schumm, P
Olopade, OI
Citation: Q. Gao et al., Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer, HUM GENET, 109(2), 2001, pp. 239-240
Authors:
Gao, Q
Tomlinson, G
Das, S
Cummings, S
Sveen, L
Fackenthal, J
Schumm, P
Olopade, OI
Citation: Q. Gao et al., Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer, HUM GENET, 107(2), 2000, pp. 186-191
Authors:
List, MA
Siston, A
Haraf, D
Schumm, P
Kies, M
Stenson, K
Vokes, EE
Citation: Ma. List et al., Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: A prospective examination, J CL ONCOL, 17(3), 1999, pp. 1020-1028